Stem Cell Clinic

Researchers: Stem cell cures are on the way

By Stem Cell Medical Center

SACRAMENTO, Calif. (KGO) -- Stem cells are the focus of debate in Sacramento where an effort is underway to use more than $1 billion in voter-approved bonds to continue experiments that may one day cure disease.

Major medical breakthroughs take time, but as public money for stem cell research is spent down, the pressure to cure something is going up.

The California Institute for Regenerative Medicine (CIRM) is about to enter a crucial stage in stem cell research, going to clinical trials. The most promising experiments could cure diabetes, HIV, sickle cell anemia, and blindness in the elderly. "You don't really get to find out whether the potential of the treatment is really going to be effective until you start to treat the patients," Alan Trounson explained.

CIRM's board is discussing how much to allocate for that trial phase. Through the 2004 voter-approved bonds under Proposition 71, it has already given out or spent half of the $3 billion, but despite the medical promise, there's little to show for it beyond basic research and several high-tech labs. Still, the agency says the breakthroughs will come over the next few years, way ahead of the rest of the world. "This would all be happening in California, all driven by this Proposition 71 money," Trounson said.

The bond money is expected to last only several more years. One option is to ask voters to approve more bonds, something taxpayer groups oppose. "When people think about bond financing, they think about a bridge, a school, a canal. But, stem cell research is just kind of out there," said Jon Coupal with the Howard Jarvis Taxpayers Association.

Rancher Diana Souza says it would be a shame to stop public funding of stem cell research. Through clinical trials at UC Davis Medical Center not financed by Prop 71 money, she says stem cells helped restore full use of her severely fractured arm. "I hope they can continue doing this because it is a miracle. It does work. And, I have a good arm to prove it," she said.

CIRM's transition plan, already submitted to Gov. Brown and lawmakers, assumes no more taxpayer support after the bond money runs out. The agency is also thinking about becoming a non-profit and letting others carry on the work.

(Copyright 2012 KGO-TV/DT. All Rights Reserved.)

Get more Politics

Tags:

Original post:
Researchers: Stem cell cures are on the way

California institute fights to continue stem cell research

By Uncategorized

Written by Nannette Miranda, ABC7

SACRAMENTO, CA - The California Institute for Regenerative Medicine, CIRM, is about to enter a crucial stage in stem cell research: going to clinical trials.

The most promising experiments could cure: diabetes, HIV, sickle cell and blindness in the elderly.

"You don't really get to find out whether the potential of the treatment is really going to be effective until you start with patients, the human subjects," CIRM's Alan Trounson said.

CIRM's board is discussing how much to allocate for that trial phase.

Through voter-approved bonds under Proposition 71, it has already given out or spent half of the $3 billion, but despite the medical promise, there's little to show for it beyond basic research and several high-tech labs.

But the agency said the breakthroughs will come over the next few years, way ahead of the rest of the world.

"This would all be happening in California, all driven by this Proposition 71 money," Trounson said.

The bond money is expected to last only several more years.

One option is to ask voters to approve more bonds, something taxpayer groups oppose.

Here is the original post:
California institute fights to continue stem cell research

Proposition 71 stem cell research funds drying up

By Stem Cell Treatment

SACRAMENTO (KABC) -- Eight years ago voters agreed to fund California's stem cell agency, hoping it would yield new treatments for various conditions. Now the agency is running out of funds and any practical cures are still years away.

The California Institute for Regenerative Medicine (CIRM) is about to enter a crucial stage in stem cell research: going to clinical trials. The most promising experiments could cure diabetes, HIV, sickle-cell anemia and blindness in the elderly.

"You don't really get to find out whether the potential of the treatment is really going to be effective until you start to treat the patients," said Alan Trounson, president of the California Institute for Regenerative Medicine.

CIRM's board is discussing how much to allocate for that trial phase. Through voter-approved bonds under Proposition 71 (The California Stem Cell Research and Cures Act), it has already given out or spent half of the $3 billion, but despite the medical promise, there's little to show for it beyond basic research and several high-tech laboratories.

But the agency says the breakthroughs will come over the next few years, way ahead of the rest of the world.

"This would all be happening in California, all driven by this Proposition 71 money," said Trounson.

The bond money is expected to last only several more years. One option is to ask voters to approve more bonds, something taxpayer groups oppose.

"When people think about bond financing, they think about a bridge, a school, a canal," said Jon Coupal, president of the Howard Jarvis Taxpayers Association. "But stem cell research is just kind of out there."

Rancher Diana Souza says it would be a shame to stop public funding of stem cell research. Through trials at UC Davis Medical Center not financed by Prop. 71 money, she says stem cells helped restore full use of her severely fractured arm.

"I hope they can continue doing this because it is a miracle. It does work. And I have a good arm to prove it," said Souza.

Visit link:
Proposition 71 stem cell research funds drying up

VistaGen Therapeutics Enters Strategic Drug Screening Collaboration With Vala Sciences

By Uncategorized

SOUTH SAN FRANCISCO, CA--(Marketwire -03/21/12)- VistaGen Therapeutics, Inc. (OTC.BB: VSTA.OB - News) (OTCQB: VSTA.OB - News), a biotechnology company applying stem cell technology for drug rescue and cell therapy, and Vala Sciences, Inc., a biotechnology company developing and selling next-generation cell image-based instruments, reagents and analysis software tools, have entered into a strategic collaboration. Their goal is to advance drug safety screening methodologies in the most clinically relevant human in vitro bioassay systems available to researchers today.

Cardiomyocytes are the muscle cells of the heart that provide the force necessary to pump blood throughout the body, and as such are the targets of most of the drug toxicities that directly affect the heart. Many of these drug toxicities result in either arrhythmia (irregular, often fatal, beating of the heart) or reduced ability of the heart to pump the blood necessary to maintain normal health and vigor.

"Our collaboration with Vala directly supports the core drug rescue applications of our Human Clinical Trials in a Test Tube platform," said Shawn K. Singh, JD, VistaGen's Chief Executive Officer. "Our high quality human cardiomyocytes combined with Vala's high throughput electrophysiological assessment capabilities is yet another example of how we are applying our stem cell technology platform within a strategic ecosystem of complementary leading-edge companies and technologies. We seek to drive our drug rescue programs forward and generate a pipeline of new, cardiosafe drug candidates."

Through the collaboration, Vala will use its Kinetic Image Cytometer platform to demonstrate both the suitability and utility of VistaGen's human pluripotent stem cell derived-cardiomyocytes for screening new drug candidates for potential cardiotoxicity over conventional in vitro screening systems and animal models. VistaGen's validated human cardiomyocyte-based bioassay system, CardioSafe 3D, will permit Vala to demonstrate the quality, resolution, applicability and ease of use of its new instrumentation and analysis software to make information-rich, high throughput measurements and generate fundamentally new insights into heart cell drug responses. Accurate, sensitive and reproducible measurement of electrophysiological responses of stem cell-derived cardiomyocytes to new drug candidates is a key element of VistaGen's CardioSafe 3D drug rescue programs. VistaGen's strategic collaboration with Vala is directed towards this goal.

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and cell therapy. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube, with modern medicinal chemistry to generate new chemical variants (Drug Rescue Variants) of once-promising small-molecule drug candidates. These are drug candidates discontinued due to heart toxicity after substantial development by pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.

Additionally, VistaGen's small molecule drug candidate, AV-101, is in Phase 1b development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S. alone. VistaGen is also exploring opportunities to leverage its current Phase 1 clinical program to enable additional Phase 2 clinical studies of AV-101 for epilepsy, Parkinson's disease and depression. To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101.

About Vala Sciences

Vala Sciences is a San Diego-based biotechnology company that develops and sells cell-image-based instrumentation, reagents and analysis software tools to academic, pharmaceutical and biotechnology scientists. Vala's IC 200 class of instrumentation, and CyteSeer Automated Image Cytometry software convert labor-intensive qualitative observations of biological changes that can take from days to months, into accurate measurements delivered automatically in minutes.

Cautionary Statement Regarding Forward Looking Statements

See more here:
VistaGen Therapeutics Enters Strategic Drug Screening Collaboration With Vala Sciences

In Treatment of Child’s Heart Defect, Doctors Find a Stem-Cell Surprise

By Stem Cell Treatment

By Ron Winslow

Doctors at Yale University have successfully implanted a biodegradablescaffold seeded with a four-year-old girls own bone-marrowcells to help treat a serious heart defect, as WSJs Heartbeat column describes.

The tube about three inches long is made of polyester material similar to that used in the manufacture of dissolvable sutures. Six months after Angela Irizarrys surgery, it had disappeared, replaced by a bioengineered conduit that acts like a normal blood vessel.

The vanishing act for the scaffold was expected, but what happens to the cells, including stem cells, that spawned the new vessel?

Much to the researchers surprise, says Chris Breuer, the Yale pediatric surgeon leading the experimental tissue-engineering project, the cells go away too.

Stem cells and certain other bone-marrow cells have building-block properties that make them the foundation for more specialized cells that grow into the bodys various tissues and structures. Researchers have long believed that stem cells transplanted into heart tissue, for instance, would be a primary component of whatever new tissue that grew as a result.

A lot of people think that when you put cells in, they turn into whatever cells you want them to turn into, Breuer tells the Health Blog. Weve clearly shown that doesnt happen in our graft.

Indeed, in experiments performed to learn how the tubes morphed into blood vessels, Breuer and his colleagues transplanted their scaffold seeded with human cells into mice bred with deficient immune systems to prevent rejection of the cells. Within a few days, the human cellswere gone, replaced within the scaffold by mouse cells, including cells characteristic of those that line the inner wall of blood vessels.

Initially, I refused to believe it, Breuer says. I redid the experiment three different ways and saw the same thing every time.

The upshot: Transplanted cells that have a quality of stem cells dont buildnew parts themselves, he says.They cause the body to induce regeneration.

See the article here:
In Treatment of Child’s Heart Defect, Doctors Find a Stem-Cell Surprise

Entest BioMedical Excited With Progress on 10 Dog Pilot Study of "Universal Donor" Stem Cell Treatment for Canine …

By Stem Cell Treatment

SAN DIEGO, CA--(Marketwire -03/21/12)- Entest BioMedical Inc. (OTCQB: ENTB.PK - News) (Pinksheets: ENTB.PK - News)

Entest BioMedical Inc. (OTCQB: ENTB.PK - News) (Pinksheets: ENTB.PK - News) and RenovoCyte LLC announced they have treated 8 canine patients of a 10 dog pilot study utilizing Canine Endometrial Regenerative Cells (CERC) licensed from Medistem Inc. (Pinksheets: MEDS.PK - News) in the treatment of canine osteoarthritis.

Previously, Entest announced the treatment of the first canine patient on November 18, 2011. Since that time Entest's McDonald Animal Hospital has treated 8 dogs in its 10 Dog Pilot Study with RenovoCyte. To date, all of the dogs participating in this study have shown dramatic improvement in their mobility and apparent reduction of pain.

Dr. Greg McDonald, Chief Veterinarian at McDonald Animal Hospital, said, "50 million CERC stem cells have been injected intravenously into eight dogs. Each dog selected for this study showed signs of arthritis. Follow-up blood tests, urinalysis and physical exams are now being scheduled for the patients that have already been treated. So far, all these canine patients have shown improvement."

Entest BioMedical Chairman David Koos stated, "Osteoarthritis is considered one of the most common causes of lameness in dogs, occurring in up to 30% of all dogs. It is caused by a deterioration of joint cartilage, followed by pain and loss of range of motion of the joint. We expect this treatment to relieve these animals from the pain associated with arthritis. This has extraordinary possibilities for dogs and may lead the way for human treatment of arthritic pain."

The CERC is a "universal donor" stem cell product that does not require matching with the recipient allowing for the generation of standardized products that can be delivered to the office of the veterinarian ready for injection. This is in stark contrast to current stem cell therapies utilized in veterinary applications which require the extraction, manipulation, and subsequent implantation of tissue from the animal being treated. CERC is the canine equivalent of Medistem's Endometrial Regenerative Cell (ERC). Medistem was recently granted approval from the FDA to initiate a clinical trial in human patients using its ERCs.

"We are extremely pleased with our research relationship with Entest BioMedical. This study of canine pets suffering from naturally occurring osteoarthritis is a better test model than laboratory induced disease because it will give us the opportunity for long term follow up of these patients. RenovoCyte sees this study as part of the supporting documentation that will be needed to obtain FDA approval for widespread usage of this therapy," said Shelly Zacharias, DVM, Director of Veterinary Operations, RenovoCyte, LLC.

A spokesperson for Entest noted the Company is also currently conducting a 10 dog safety study on its immune-therapeutic cancer vaccine for dogs, having treated 3 dogs so far.

About Entest BioMedical Inc.:Entest BioMedical Inc. (http://www.entestbio.com) is a veterinary biotechnology company focused on developing therapies that harness the animal's own reparative / immunological mechanisms. The Company's products include an immuno-therapeutic cancer vaccine for canines (ImenVax). ImenVax is less invasive and less traumatic in treating cancer. Additionally, the Company serves as the contract research organization conducting a pilot study on a stem cell based canine osteoarthritis treatment (developed by RenovoCyte LLC) utilizing a 'universal donor' stem cell. Entest is also building a network of veterinary hospitals (with its initial location in Santa Barbara, CA and anticipates acquiring other veterinary hospitals in California) -- which serve as distribution channels for its products.

DisclaimerThis news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Read more:
Entest BioMedical Excited With Progress on 10 Dog Pilot Study of "Universal Donor" Stem Cell Treatment for Canine ...

Rescue dogs get stem cell treatment

By Stem Cell Treatment

(WRC/NBC) There is a breakthrough treatment using stem cellsthat's helping search-and-rescue dogs.

Theanimals played key roles on Sept. 11, 2001and in other disasters. Nowthe therapy is part of the recovery process after years of heroic work.

Red's first assignment as a search, rescue and recovery dog was at the Pentagon following the 911 attacks.

Her handler, Heather Roche said "she handled it like a pro."

"She didn't care about the machinery, bobcats moving the debris and all the people and everybody in their Tyvek suits looking funny with the respirators, and she didn't mind any of it and went to work," Roche said.

Now the 911 hero is in bad shape. All those years of rescue work, and a 12-foot fall from a ladder, have taken a toll.

Arthritis forced her into retirement in July.

On Tuesday, the 12-year-old black Labrador received a breakthrough stem cell treatment to ease her pain and give her more mobility.

The procedure was performed by Dr. John Herrity at the Burke Animal Clinic, where he's done more than two dozen stem cell operations.

Medivet America developed the technology and donated the cost of the procedure.

Original post:
Rescue dogs get stem cell treatment

SanBio Announces Enrollment of First Cohort of Patients in Its Clinical Trial of Stem Cell Therapy for Chronic Stroke

By Uncategorized

MOUNTAIN VIEW, Calif., March 20, 2012 /PRNewswire/ -- SanBio Inc. today announced the successful enrollment of the first dose cohort of patients in its Phase 1/2a clinical trial testing the safety and efficacy of a novel allogeneic stem cell therapy product, SB623, in patients suffering from chronic deficits resulting from previous stroke injuries. The first 6 patients, of a total of 18, have been successfully administered SB623. The trial is being conducted at Stanford University and the University of Pittsburgh. No safety concerns have been reported. For details regarding this clinical trial, please refer to http://www.strokeclinicaltrial.org.

SB623 is derived from adult bone marrow and has shown safety and efficacy in rodent models of chronic stroke. "This represents a major milestone in the human clinical testing of this important new approach for regenerative medicine", said Keita Mori, SanBio CEO. "We are pleased to learn that the initial dose level was well tolerated."

SB623 is being delivered to the damaged region of the brains of patients who have suffered an ischemic stroke. Product safety is the primary focus of the study but various measurements of efficacy are also being tested.

"The successful completion of the initial dose cohort is a major step in any first-in-human study", said Dr. Ernest Yankee, SanBio's Vice President of Development. "We are looking forward to initiating the next two dose cohorts and wrapping up the study. The safety findings thus far are very encouraging"

About SB623: SB623 is a proprietary cell therapy product consisting of cells derived from genetically engineered bone marrow stromal cells obtained from healthy adult donors. SB623 is administered adjacent to the area damaged by stroke and functions by producing proteins that aid the regenerative process.

About SanBio: SanBio is a privately held San Francisco Bay Area biotechnology company focused on the discovery and development of new regenerative cell therapy products.

For more information: http://www.san-bio.com

See the rest here:
SanBio Announces Enrollment of First Cohort of Patients in Its Clinical Trial of Stem Cell Therapy for Chronic Stroke

Editorial: Medical case gets serious treatment

By Stem Cell Treatment

When a Bonita Springs doctor had his state license suspended after yet another stem-cell treatment case, his attorney issued a statement saying he had done nothing wrong and a second doctor was involved in treating a 77-year-old heart patient, who later died.

In response, rather than acquiesce, the state has gotten even more involved, issuing an emergency license restriction against that doctor, Konstantine K. Yankopolus, of Fort Myers.

That tells us the Florida Department of Health is focused on getting answers to what happened and assuring public health and safety is protected.

The lead doctor, Zannos Grekos, was in the news previously for stem-cell treatment on a 66-year-old breast cancer patient, who later fell, suffering severe brain damage and being taken off life support. The state ordered Grekos to suspend treatment with stem cells in Florida, though he still was allowed to conduct educational seminars about stem-cell therapy and arrange for patients to go for treatment in the Dominican Republic.

The state's order against Yankopolus says he knew Grekos was under a license restriction when Yankopolus agreed to assist in performing the stem-cell treatment for the now-deceased 77-year-old.

The order also notes that Yankopolus initially reported no stem-cell treatment was involved in the patient's care. That chart, the order says, was later changed by Yankopolus, who called it "a misunderstanding."

No wonder the state has questions about all this.

Integrity is at issue for these doctors and the medical community in general.

Also in the spotlight is how our state regulators choose to respond.

We can be grateful for Florida's Sunshine Laws for assuring public access to public records as this important investigation moves forward.

More:
Editorial: Medical case gets serious treatment

Tai Chi Shown to Vastly Improve Parkinson’s Symptoms

By Stem Cell Doctors

With recent remarks made by Republican Presidential nominee Rick Santorum on his stance on Stem Cell Research, people suffering from Parkinsons disease and other afflictions which can benefit from Stem Cell research have opened up Pandoras Box in their search for non-traditional methods to reduce symptoms. Recent medical studies as well as an in-depth report posted at BeWellBuzz.com have confirmed that the ancient martial art of Tai chi can significantly reduce some of the worst physical problems of Parkinson's disease.

Las Vegas, Nevada (PRWEB) March 20, 2012

Parkinson's disease is a nervous system disorder which commonly develops in humans of age 50 and above, however, many people, such as Hollywood actor Michael J. Fox have been diagnosed with this affliction much earlier in life. Parkinsons carries certain specific symptoms such as constant blinking, lack of facial expressions, shaking, loss of balance and coordination, and other irregular bodily reactions, and is caused primarily by the destruction of the nerve cells in the brain which makes dopamine, a neurotransmitter responsible for the transfer of pleasure and reward feelings in the center of the brain.

Medications may help control some things, like tremors, but many drugs are not as good at helping the so-called axial symptoms of Parkinson's disease, which include problems with balance and walking. It is for this reason that a recent study was completed at Johns Hopkins School of Medicine in Baltimore which showed significant improvements to these symptoms which have plagued Parkinsons patients for decades.

According to the study, doctors assigned 195 people with mild-to-moderate Parkinson's disease to one of three groups: Tai Chi classes, Exercise with Weights and a third group which completed a program of seated stretching exercises. After six months, people who had been taking tai chi were able to lean farther forward or backward without stumbling or falling compared to those who had been doing resistance training or stretching. They were also better able to smoothly direct their movements. And they were able to take longer strides than people in the other two groups.

"The results from this study are quite impressive," says Ray Dorsey, MD, MBA, a neurologist and associate professor at Johns Hopkins School of Medicine in Baltimore. "It's always difficult to compare results across studies, but the magnitude of the impact that they had is larger, in some cases, than what is seen with medications in Parkinson's."

"This is a very encouraging study," says Chenchen Wang, MD, associate professor at Tufts University School of Medicine in Boston who has studied the benefits of Tai Chi on Osteoarthritis and Fibromyalgia in the past. "Most of our previous studies have measured pain, depression, and anxiety, which are subjective measures. These results are very impressive because they used objective measurements,"

To learn more about the recent discovery and other ways that Tai Chi can improve other conditions, please visit the article posted at BeWellBuzz.com posted below.

Tai Chi and Parkinson's Disease

About BeWellBuzz.com

See original here:
Tai Chi Shown to Vastly Improve Parkinson’s Symptoms

→←